NEW YORK, NY / ACCESSWIRE / November 19, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Tactile Systems Technology, Inc. (NASDAQ:TCMD)
Class Period: May 7, 2018 - June 8, 2020
Lead Plaintiff Deadline: November 30, 2020
The TCMD lawsuit alleges that Tactile Systems Technology, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile's pneumatic compression devices was materially smaller; (2) to induce sales growth and share gains, Tactile and/or its employees were engaged in illicit and illegal sales and marketing activities in violation of applicable federal and state rules and public payer regulations; (3) the foregoing illicit and illegal sales and marketing activities increased the risk of a Medicare audit of Tactile's claims and criminal and civil liability; (4) Tactile's revenues were in part the product of unlawful conduct and thus unsustainable; and that as a result of the foregoing, (5) Defendants' public statements, including Tactile's year-over-year revenue growth, the purported growth drivers, and the effectiveness of Tactile's internal controls over financial reporting were materially false and misleading at all relevant times.
Learn about your recoverable losses in TCMD: http://www.kleinstocklaw.com/pslra-1/tactile-systems-technology-inc-loss-submission-form?id=11081&from=1
Biogen Inc. (NASDAQ:BIIB)
Class Period: October 22, 2019 - November 6, 2019
Lead Plaintiff Deadline: January 12, 2021
According to the complaint, Biogen Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Learn about your recoverable losses in BIIB: http://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form?id=11081&from=1
Alibaba Group Holding Limited (NYSE:BABA)
Class Period: October 21, 2020 - November 3, 2020
Lead Plaintiff Deadline: January 12, 2021
The BABA lawsuit alleges that Alibaba Group Holding Limited made materially false and/or misleading statements and/or failed to disclose that: (1) Ant Small and Micro Financial Services Group Co., Ltd. ("Ant Group"), a financial technology company in which Alibaba owns a 33% equity interest, did not meet listing qualifications or disclosure requirements for certain material matters; (2) certain impending changes in the Fintech regulatory environment would impact Ant Group's business; (3) as a result of the foregoing, Ant Group's initial public offering was reasonably likely to be suspended; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in BABA: http://www.kleinstocklaw.com/pslra-1/alibaba-group-holding-limited-loss-submission-form?id=11081&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: